An exploratory phase II trial of low-dose decitabine and sintilimab combined with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma.
Authors
Fei Su (ORCID: https://orcid.org/0000-0002-5498-6130)
An exploratory phase II trial of low-dose decitabine and sintilimab combined with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma.
Fei Su, Liang Zong, Wenqing Hu, Yunyi Du et al.
Journal
Journal of Clinical Oncology
Topics
Gastric Cancer Management and Outcomes
article
An exploratory phase II trial of low-dose decitabine and sintilimab combined with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma.
Fei Su, Liang Zong, Wenqing Hu, Yunyi Du, Bo Yang, Ning Ma, Xiaoling Zhang, Jun Zhao, Wei Yang
article en
Abstract
No abstract available for this paper.
Publication Tag
Journal of Clinical OncologyVol. 43(4_suppl)
Institutions
Shanxi Medical University (CN), Changzhi Medical College (CN)
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
An exploratory phase II trial of low-dose decitabine and sintilimab combined with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma. — Fei Su, Liang Zong, et al. · Journal of Clinical Oncology (2025) | TGRS Research Map | TGRS